Exploiting alloreactivity for tumour immunotherapy.

about

Antigen-specific cellular immunotherapy of leukemia.Engineering T cells for cancer therapy.

P2860

Q36240201-1078BF18-4CFB-4804-A395-2297C8D52662 Q36298319-D7C27977-70DB-4CEE-93C8-79BFDB335946

P2860

Exploiting alloreactivity for tumour immunotherapy.

Item

http://www.wikidata.org/entity/Q35813110

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Exploiting alloreactivity for tumour immunotherapy.

@ast

Exploiting alloreactivity for tumour immunotherapy.

@en

type

Item

label

Exploiting alloreactivity for tumour immunotherapy.

@ast

Exploiting alloreactivity for tumour immunotherapy.

@en

prefLabel

Exploiting alloreactivity for tumour immunotherapy.

@ast

Exploiting alloreactivity for tumour immunotherapy.

@en

P1476

Exploiting alloreactivity for tumour immunotherapy.

@en

P2093

Bendle G

http://www.w3.org/2001/XMLSchema#string

Downs AM

http://www.w3.org/2001/XMLSchema#string

Gao L

http://www.w3.org/2001/XMLSchema#string

Gillmore R

http://www.w3.org/2001/XMLSchema#string

Holler A

http://www.w3.org/2001/XMLSchema#string

Morris E

http://www.w3.org/2001/XMLSchema#string

Stauss HJ

http://www.w3.org/2001/XMLSchema#string

Xue S

http://www.w3.org/2001/XMLSchema#string

P2860

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

Immunotherapy with CTLs restricted by nonself MHC.

Type 1 T regulatory cells.

Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies.

CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease

CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.

P304

227-229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1741-6892.2004.00493.X

http://www.w3.org/2001/XMLSchema#string

P478

87 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15209922

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Exploiting alloreactivity for tumour immunotherapy.

about

P2860

P2860

Exploiting alloreactivity for tumour immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921